SELLAS Life Sciences Group, Inc. Current Liabilities
SELLAS Life Sciences Group, Inc. (SLS) had Current Liabilities of $7.57 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Liabilities, Current $7.57M.
- 2026-03-31: Liabilities, Current $6.46M.
- 2025-12-31: Liabilities, Current $7.02M.
- 2025-09-30: Liabilities, Current $5.92M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.57M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $6.46M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $7.02M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $5.92M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $6.00M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $6.89M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $9.51M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $10.61M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $12.04M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $14.44M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $13.73M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $11.73M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $13.42M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $15.51M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $15.52M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $12.55M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $12.19M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $10.68M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $4.98M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $5.32M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $4.24M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $5.97M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $12.34M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $4.22M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $4.33M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $3.63M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $5.29M 10-K · filed 2021-03-23 | |
| 2019-09-30 | $5.57M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $5.40M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $5.80M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $5.97M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $12.00M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $24.85M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $25.75M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $24.57M 10-K · filed 2019-03-22 | |
| 2017-09-30 | $28.02M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $34.54M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $36.27M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $5.76M 10-K · filed 2018-04-13 | $30.40M 10-K · filed 2017-03-15 |
| 2016-09-30 | $42.54M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $47.22M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $42.22M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $57.07M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $37.09M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $38.11M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $33.96M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $27.23M 10-K/A · filed 2016-04-15 | |
| 2014-09-30 | $31.59M 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $33.41M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $26.84M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $62.47M 8-K · filed 2015-12-04 | $62.45M 10-K · filed 2014-03-17 |
| 2013-09-30 | $36.51M 10-Q/A · filed 2013-11-07 | |
| 2013-06-30 | $25.75M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $26.38M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $15.92M 10-K · filed 2014-03-17 | |
| 2012-09-30 | $10.06M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $9.32M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $27.39M 10-Q · filed 2012-05-14 | |
| 2011-12-31 | $11.20M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $21.46M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $19.55M 10-Q/A · filed 2011-10-28 | $16.82M 10-Q · filed 2011-08-15 |
| 2010-12-31 | $5.03M 10-K · filed 2012-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |